ArticleFrontiers in pharmacology2026
Case Report: Inotersen reintroduction after thrombocytopenia in hereditary transthyretin amyloidosis: a case series.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: ATTRv amyloidosis is a progressive multisystem disease caused by pathogenic variants in the transthyretin (TTR) gene. Inotersen is approved for the treatment of polyneuropathy in adults with hereditary transthyretin mediated amyloidosis, but thrombocytopenia is a clinically relevant adverse event that may require treatment interruption or discontinuation. Evidence guiding reintroduction of inotersen after thrombocytopenia is limited. Case Presentation: We retrospectively reviewed two men with genetically confirmed ATTRv treated at two centers in Argentina who developed treatment-emergent thrombocytopenia during inotersen therapy. Patient 1 was a 71-year-old man with late-onset mixed neurologic and cardiac ATTRv due to TTR p.Val50Met who developed grade 2 thrombocytopenia after 22 weeks of treatment, with a platelet nadir of 58 × 10^9/L. Patient 2 was a 52-year-old man with early-stage neuropathic ATTRv due to TTR p.Val50Met who developed grade 4 thrombocytopenia after 65 weeks, with platelet counts below 20 × 10^9/L, and had recurrent thrombocytopenia during an initial reintroduction attempt. Intervention and Outcomes: After platelet recovery and exclusion of alternative causes of thrombocytopenia, both patients underwent a structured 7-day stepwise short-term reintroduction protocol under close hematologic monitoring. Following protocol completion, inotersen was resumed at 284 mg every 2 weeks. During follow-up, neither patient developed recurrent severe thrombocytopenia, and both maintained biochemical evidence of transthyretin suppression. Conclusion: In this small case series, inotersen reintroduction after thrombocytopenia was feasible in two ATTRv patients when implemented with a structured stepwise protocol and close platelet monitoring, but these findings are hypothesis-generating and not generalizable. One reintroduction occurred outside prescribing recommendations for severe thrombocytopenia and should not be interpreted as a recommended strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.